Lytix Biopharma ASA is a clinical-stage biotechnology company based in Oslo, Norway, with an additional office in Tromso. Founded in 2003, the company specializes in developing innovative cancer immunotherapies designed to activate the patient's immune system against tumors. Its lead product, LTX-315, is an oncolytic peptide that modifies the tumor microenvironment by releasing potent immune stimulants and tumor antigens. In addition to LTX-315, Lytix Biopharma is also advancing other products in its pipeline, including LTX-401. The company is dedicated to research and development in the fields of cancer therapeutics and anti-microbials.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.